Rituximab

• Description:

  Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.

• Product Name Alternative:

  Anti-Human CD20 type I, Chimeric Antibody; HSDB 7455; IDEC-C2B8

• UNSPSC:

  12352203

• Hazard Statement:

  H372

• Target:

  CD20; Radionuclide-Drug Conjugates (RDCs)

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Antibody-drug Conjugate/ADC Related; Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/Rituximab.html

• Purity:

  99.85

• Solubility:

  H2O

• Smiles:

  [Rituximab]

• Molecular Weight:

  (143.47 kDa)

• Precautions:

  P260-P264-P270-P501

• References & Citations:

  [1]Kamburova EG, et al. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant. 2012 Feb;12 (2) :341-50.|[2]Manches O, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003 Feb 1;101 (3) :949-54.|[3]Byrd JC, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002 Feb 1;99 (3) :1038-43.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  Launched

• Isoform:

  RDC Antibody

• CAS Number:

  [174722-31-7]